SARS -CoV-2 T-cell immunity to variants of concern following vaccination

Kathleen Gallagher, Mark B. Leick, Rebecca C. Larson, Trisha R. Berger, Katelin Katsis, Jennifer Yam, Gabrielle Brini, Korneel Grauwet

bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 34 citations · 46 references

DOIFull text

Open access

Concepts

Abstract

SUMMARY Recently, two mRNA vaccines to severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) have become available, but there is also an emergence of SARS-CoV-2 variants with increased transmissibility and virulence 1–6 . A major concern is whether the available vaccines will be equally effective against these variants. The vaccines are designed to induce an immune response against the SARS-CoV-2 spike protein 7, 8 , which is required for viral entry to host cells 9 . Immunity to SARS-CoV-2 is often evaluated by antibody production, while less is known about the T-cell response. Here we developed, characterized, and implemented two standardized, functional assays to measure T-cell immunity to SARS-CoV-2 in uninfected, convalescent, and vaccinated individuals. We found that vaccinated individuals had robust T-cell responses to the wild type spike and nucleocapsid proteins, even more so than convalescent patients. We also found detectable but diminished T-cell responses to spike variants (B.1.1.7, B.1.351, and B.1.1.248) among vaccinated but otherwise healthy donors. Since decreases in antibody neutralization have also been observed with some variants 10–12 , investigation into the T-cell response to these variants as an alternative means of viral control is imperative. Standardized measurements of T-cell responses to SARS-CoV-2 are feasible and can be easily adjusted to determine changes in response to variants.

References

46